Zenas Biopharma, Inc.
A clinical-stage biopharmaceutical company developing therapies for autoimmune diseases. Its lead candidate, obexelimab, is a bifunctional antibody that calms overactive B cells without destroying them, and it met its primary goal in a late-stage trial for the rare condition IgG4-related disease. Founded in 2020 by serial entrepreneur Lonnie Moulder, the company takes its name from the ancient Greek "Zenas," meaning "gift of Zeus."
Bought 492.9K
Bought 2.36M
Bought 882.4K
Bought 945.5K
Bought 557.3K
Bought 766.2K
Bought 485.6K
Bought 19.9K
Bought 10.0K
Granted 1.6K
Granted 974
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Moulder Leon O JrChief Executive Officer, Director · 23 transactions | — | 5.84M | — | 492.9K | — |
| George Simeon +1 co-filer10% owner · 8 transactions | — | 5.04M | — | 2.36M | — |
| Enavate Sciences GP, LLC +1 co-filer10% owner · 2 transactions | — | 3.76Mas of Sep 2024 | — | 882.4K | — |
| Nunn Jason RaleighDirector · 5 transactions | — | 3.12M | — | 945.5K | — |
| Enright Patrick GDirector · 6 transactions | — | 2.62M | — | 557.3K | — |
| Fairmount Funds Management LLC +3 co-filersDirector · 7 transactions | — | 2.36M | — | 766.2K | — |
| Lu HongboDirector · 6 transactions | — | 849.7K | — | 485.6K | — |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% owner · 3 transactions | — | 801.6Kas of Sep 2024 | — | — | — |
| Allen Patricia LDirector · 4 transactions | — | 19.9K | — | 19.9K | — |
| Xiao TingDirector · 1 transaction | — | 10.0Kas of Feb 2025 | — | 10.0K | — |
| Fox Jennifer A.See Remarks · 1 transaction | — | 1.6K | 1.6K | — | — |
| Farmer Joseph LSee Remarks · 1 transaction | — | 974 | 974 | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +6.52M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.